metformin

P1/2, N=25, Recruiting, Universita Degli Studi Di Milano Bicocca | Not yet recruiting --> Recruiting

P2, N=111, Completed, University of Chicago | Active, not recruiting --> Completed

P=N/A, N=70, Not yet recruiting, Foundation University Islamabad

These findings indicate that BA and resveratrol enhance the antineoplastic activity of metformin in SKOV3 OC cells by suppressing proliferative and migratory capacities and modulating inflammatory mediators such as IL-17, NF-κB, and MDK. However, since toxicity assessments in non-cancerous cells were not performed, the safety profile of this combination remains unclear and requires further investigation in non-cancerous models.

The combination of PFD, MET, and BM-MSCs offered superior therapeutic efficacy in treating BLM-induced pulmonary fibrosis compared to individual treatments. This multimodal approach effectively targets oxidative stress, inflammation, apoptosis, and fibrosis, suggesting strong potential for future clinical application.

The typical therapeutic approach includes surgery plus cytotoxic drugs such as carboplatin and paclitaxel. In recent years, the advent of poly ADP-ribose polymerase (PARP) inhibitors such as olaparib has offered additional treatment opportunities for patients with BRCA mutations or homologous recombination deficiencies...Furthermore, it can affect the phenotype of other cells of the tumor microenvironment such as macrophages and T cells. In this review, we summarize the main characteristics of ovarian cancer and describe preclinical studies and clinical trials involving metformin as a therapeutic agent for this disease.

Analysis of patient datasets revealed a positive correlation between ERβ gene (ESR2) expression and senescence-related markers in obese luminal breast cancer patients, particularly MCL1, BCL2L1, CCL2, and ICAM1. These findings indicate that ERβ exhibits a key role as mediator of obesity-induced tumor alterations by promoting senescence-related markers, and that metformin's ability to target ERβ offers a potential strategy to suppress senescence-driven malignancy and improve therapeutic outcomes of obese luminal breast cancer patients.

P=N/A, N=34, Recruiting, University of Baghdad

P1, N=30, Completed, Bristol-Myers Squibb | Recruiting --> Completed

These findings indicate that, under the dosing and exposure conditions examined, metformin was not associated with measurable tumor-protective or tumor-preventive effects in MEN1-related PNETs. The study highlights important methodological considerations, including exposure timing and statistical power, and supports the need for prospective studies initiating metformin prior to tumor development in genetically predisposed populations.

In humanized liver mice, quinidine coadministration increased AMT exposure (AUCRobs = 2.87); in rats, AMT coadministration elevated metformin (MATE1 substrate) area under the curve by 68%...SIGNIFICANCE STATEMENT: This study reveals that the novel antidepressant ammoxetine poses dual drug interaction risks as a cytochrome P450 2D6 (CYP2D6) substrate/inhibitor affecting metabolism and a multidrug and toxin extrusion protein 1 inhibitor impairing renal excretion. Using humanized models and static mechanistic models, the interactions were validate in vivo and characterize the proposed metabolism-transport interaction cascade, delineating clinically relevant risks, including amplified ammoxetine exposure with strong CYP2D6 inhibition and heightened vulnerability in CYP2D6 poor metabolizers.

P1, N=14, Completed, Boehringer Ingelheim | Active, not recruiting --> Completed